Growth Metrics

Merck (MRK) EPS (Weighted Average and Diluted) (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -243.33%
Dec 31, 2025 -48.28%
Sep 30, 2025 31.82%
Jun 30, 2025 -12.44%
Mar 31, 2025 35.81%
Dec 31, 2024 19.35%
Sep 30, 2024 -42.06%
Jun 30, 2024 14.44%
Mar 31, 2024 489.58%
Dec 31, 2023 -125.81%
Sep 30, 2023 179.15%
Jun 30, 2023 -311.71%
Mar 31, 2023 -5.93%
Dec 31, 2022 -7.81%
Sep 30, 2022 -17.42%
Jun 30, 2022 -8.82%
Mar 31, 2022 41.67%
Dec 31, 2021 -33.33%
Sep 30, 2021 195.08%
Jun 30, 2021 -43.52%
Mar 31, 2021 230.12%
Dec 31, 2020 -171.55%
Sep 30, 2020 26.09%
Jun 30, 2020 -26.98%
Mar 31, 2020 36.96%
Dec 31, 2019 24.32%
Sep 30, 2019 -28.16%
Jun 30, 2019 -8.04%
Mar 31, 2019 62.32%
Dec 31, 2018 -5.48%
Sep 30, 2018 15.87%
Jun 30, 2018 133.33%
Mar 31, 2018 171.05%
Dec 31, 2017 -1,800.00%
Sep 30, 2017 -102.82%
Jun 30, 2017 26.79%
Mar 31, 2017 366.67%
Dec 31, 2016 -126.92%
Sep 30, 2016 81.40%
Jun 30, 2016 7.50%
Mar 31, 2016 17.65%
Dec 31, 2015 -46.87%
Sep 30, 2015 166.67%
Jun 30, 2015 -27.27%
Mar 31, 2015 -86.80%
Dec 31, 2014 706.45%
Sep 30, 2014 -54.41%
Jun 30, 2014 19.30%
Mar 31, 2014 111.11%
Dec 31, 2013 -28.95%
Sep 30, 2013 26.67%
Jun 30, 2013 -42.31%
Mar 31, 2013 79.31%
Dec 31, 2012 -48.21%
Sep 30, 2012 -3.45%
Jun 30, 2012 3.57%
Mar 31, 2012 14.29%
Dec 31, 2011 -10.91%
Sep 30, 2011 -15.38%
Jun 30, 2011 91.18%
Mar 31, 2011 312.50%
Dec 31, 2010 -245.45%
Sep 30, 2010 -54.17%
Jun 30, 2010 166.67%
Mar 31, 2010 -96.56%
Dec 31, 2009 62.73%
Sep 30, 2009 117.57%
Jun 30, 2009 10.45%